Outcomes of Pembrolizumab plus chemotherapy for patients with metastatic non-squamous NSCLC: Real-world evidence
This real-world evidence suggests that immunochemotherapy generally improves OS in mNSCLC. Subgroup analysis showed no survival benefit for patients with ECOG >1 or bone metastasis, but a benefit for patients with M1c stage.
Authors
- Philipp Morakis (ORCID: https://orcid.org/0009-0005-2591-3273)
- Felix Herth (ORCID: https://orcid.org/0000-0002-7638-2506)
- Daria B. Kokh (ORCID: https://orcid.org/0000-0002-4687-6572)
- Irina Surovtsova (ORCID: https://orcid.org/0009-0003-4263-6250)
Institutions
- Heidelberg University (DE)
- Heidelberg University (US)
Publication Details
- Journal
- Pulmonology
- Published
- 2025-02-05
- DOI
- https://doi.org/10.1080/25310429.2025.2457856
- Citations
- 6
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 6.27